Spyre Therapeutics, Inc. SYRE
85.69
(1.40)
(1.61%)
as of 25 Sep
- Market cap
- $7.7B
- P/E
- 0.0×
Follow SYRE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(63.28%) | (33.69%) | (42.63%) | (28.52%) | |
| (32.19%) | (22.39%) | (26.91%) | (20.90%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(32.50%) | (21.58%) | (26.43%) | (16.12%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(2.68) | (2.64) | (2.36) | (2.47) | |
Free Cash Flow |
(161.87) | (169.25) | (185.63) | (208.94) | |
| Other line items | |||||
Cash ROIC |
(17.20%) | (11.50%) | (13.14%) | (9.30%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.09 | 1.09 | 1.03 | 1.17 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.68) | (2.64) | (2.36) | (2.47) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates